Characterization and Outcomes of Disease Progression in 52 Patients Treated with < b > < i > BRAF < /i > < /b > -V600 + MEK Inhibitors for Advanced Melanoma

Conclusion: Our study shows that, for patients treated withBRAF-V600 + MEK inhibitors who lose response, disease progression was aggressive and had poor outcomes. Most patients had CNS metastases and low rates of therapeutic response to any subsequent therapy.Dermatology
Source: Dermatology - Category: Dermatology Source Type: research